M Saunes1, T I Lund Nilsen, T B Johannesen. 1. Department of Dermatology, St Olavs Hospital, and Norwegian University of Science and Technology, Trondheim, Norway. marit.saunes@ntnu.no
Abstract
BACKGROUND: Studies from different countries have reported an increased incidence of primary cutaneous lymphomas over the last decades. OBJECTIVES: To estimate the incidence rates of primary cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF)/Sézary syndrome (SS) in Norway, and to compare these rates with those reported from other countries. METHODS: Data from the Cancer Registry of Norway on non-Hodgkin lymphomas during the period 1980-2003 were analysed. RESULTS: In total, 337 cases of CTCL were reported to the Cancer Registry during the study period, of which 262 cases were classified as MF/SS. The incidence rate of CTCL increased significantly (P(trend) < 0.001) from 0.16 (95% confidence interval, CI 0.11-0.20) per 100,000 person-years in 1980-84 to 0.29 (95% CI 0.22-0.36) per 100,000 person-years in 2000-2003. The incidence of MF/SS also increased during the same period (P(trend) = 0.05) from 0.15 (95% CI 0.10-0.19) per 100,000 person-years to 0.18 (95% CI 0.13-0.24) per 100,000 person-years. CONCLUSIONS: The incidence of both CTCL and MF/SS increased in Norway during the period 1980-2003.
BACKGROUND: Studies from different countries have reported an increased incidence of primary cutaneous lymphomas over the last decades. OBJECTIVES: To estimate the incidence rates of primary cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF)/Sézary syndrome (SS) in Norway, and to compare these rates with those reported from other countries. METHODS: Data from the Cancer Registry of Norway on non-Hodgkin lymphomas during the period 1980-2003 were analysed. RESULTS: In total, 337 cases of CTCL were reported to the Cancer Registry during the study period, of which 262 cases were classified as MF/SS. The incidence rate of CTCL increased significantly (P(trend) < 0.001) from 0.16 (95% confidence interval, CI 0.11-0.20) per 100,000 person-years in 1980-84 to 0.29 (95% CI 0.22-0.36) per 100,000 person-years in 2000-2003. The incidence of MF/SS also increased during the same period (P(trend) = 0.05) from 0.15 (95% CI 0.10-0.19) per 100,000 person-years to 0.18 (95% CI 0.13-0.24) per 100,000 person-years. CONCLUSIONS: The incidence of both CTCL and MF/SS increased in Norway during the period 1980-2003.
Authors: Briseis Aschebrook-Kilfoy; Pierluigi Cocco; Carlo La Vecchia; Ellen T Chang; Claire M Vajdic; Marshall E Kadin; John J Spinelli; Lindsay M Morton; Eleanor V Kane; Joshua N Sampson; Carol Kasten; Andrew L Feldman; Sophia S Wang; Yawei Zhang Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat Journal: Cochrane Database Syst Rev Date: 2013-08-29
Authors: Philippe Lefrançois; Pingxing Xie; Linghua Wang; Michael T Tetzlaff; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Nathalie Provost; Martin Gilbert; Xiao Ni; Denis Sasseville; David A Wheeler; Madeleine Duvic; Ivan V Litvinov Journal: Oncoimmunology Date: 2018-05-31 Impact factor: 8.110
Authors: Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Michelle A Jennings; David R Risser; Pamela Gangar; Elena Netchiporouk; Linda Moreau; Victor G Prieto; Denis Sasseville; Madeleine Duvic Journal: Cancer Med Date: 2015-07-01 Impact factor: 4.452
Authors: Rebeca Manso; Nerea Martínez-Magunacelaya; Itziar Eraña-Tomás; Verónica Monsalvez; José L Rodríguez-Peralto; Pablo-L Ortiz-Romero; Carlos Santonja; Ion Cristóbal; Miguel A Piris; Socorro M Rodríguez-Pinilla Journal: PLoS One Date: 2018-06-12 Impact factor: 3.240